TD Cowen raised the firm’s price target on Illumina (ILMN) to $140 from $115 and keeps a Hold rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies “already soft guided” 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target raised to $155 from $142 at Evercore ISI
- Illumina price target raised to $144 from $114 at Guggenheim
- Illumina price target raised to $130 from $112 at Canaccord
- Illumina price target raised to $130 from $105 at JPMorgan
- Illumina price target raised to $110 from $100 at Barclays